CKM focus Target opportunities around chronic metabolic diseases with multi-organ implications, aligning HTD1801 and HTD4010 programs to cardiovascular-kidney-metabolic syndrome management and comorbidity co-treatment needs.

Late-stage signals Leverage Fast Track and Orphan Drug designations for HTD1801 to pursue partnerships or licensing deals that emphasize accelerated development timelines and regulatory advantages in select markets.

Clinical momentum Capitalize on recent Phase 2 data and ongoing presentations at EASL and related conferences to generate demand for collaboration on additional studies, biomarker strategies, and expanded indications.

Global expansion Explore regional partnerships to scale manufacturing and distribution, leveraging the HK public listing experience and China project recognition to access Asian markets with cost-efficient supply and local regulatory support.

Financial partnering Engage with investors and strategic financiers by highlighting a sizable revenue window and a diversified asset pipeline, pursuing co-development or milestone-based financing to accelerate commercialization.